Unprecedented Study Results Demonstrating Topical Wound Oxygen Effectiveness Presented at Major Wound Care Conferences
Press Release
By:
Ref: PR Newswire
Published: 05/22/2018
The authors noted in their conclusions that "Of the 115 ulcers under treatment with Topical Wound Oxygen in two years, 64.4% achieved complete closure" also "Of the ulcerations that have not reached full closure, the majority have decreased in size since initiation of topical oxygen" it was noted that "a number of patients stated they had significant pain relief with the usage of the Topical Wound Oxygen device."
"We are delighted to see further scientific evidence supporting the effectiveness of our unique multi-modality TWO2 therapy in healing chronic ulcerations being presented at both the SAWC and EWMA conferences, which are the largest annual multi-disciplinary wound care conferences held in the USA and Europe respectively. AOTI remains committed to fostering the development of the strongest scientific evidence demonstrating both the healing and health economic benefits of our patented Topical Wound Oxygen (TWO2) homecare therapy," stated Dr. Mike Griffiths, CEO and President of AOTI.
The full abstract entitled "A Retrospective Review of Pressurized Cyclical Topical Oxygen as an Adjunct Treatment in Healing Chronic Wounds and Ulcerations" can be downloaded using the following link:
About AOTI
AOTI Inc. is a private company based in Oceanside, California USA and Galway, Ireland, that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is unsurpassed in fully closing Diabetic, Venous and Pressure ulcers alike.
For more information see: www.aotinc.net
Contact:
Dr. Mike Griffiths
CEO and President
(760) 672 1920
195689@email4pr.com
SOURCE AOTI Inc.